Bridging the Gap: Index Volume [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

12th World AIDS Conference

patients *patients 141

-- Keyword

Abstract

s equi infection in AIDS
e-control study in AIDS
bacterial pneumonia in
teremia in HIV-infected
ons in HIV-hospitalized
heter infections in AIDS
DR-TB) in HIV positive
ns among HIV-positive
sis (TB) in HIV-infected
tarting HAART in AIDS
a cohort of HIV-infected
patitis in HIV-1-infected
olicy for HIV-infected
ection in HIV-1 infected
sis (TB) cases in AIDS
erculosis in adult AIDS
ycobacterial disease in
culous lymphadenitis in
nfection in HIV infected
Brazil/HIV screening in
mpliance of tuberculosis
bia?/How likely are TB
June 97/Profile of HIV
m Brazilian HIV-infected
use of tuberculin tests in
sis (TB) in HIV infected
cterial diseases in HIV+
sample of HIV-infected
AC) isolates from AIDS
ary PCP prophylaxis in
hylaxis after HAART in
tal warts in HIV positive
ology by M-PCR in STD
and HIV prevalence in
V RNA in asymptomatic
is (OC) in HIV-infected
me/Candidemia in HIV+
vironmental risk for HIV
histoplasmosis in AIDS
I infections in HIV/AIDS
of toxoplasmosis in HIV
n bieneusi infections in
ected and non-infected
h cohort of HIV-infected
usi strains isolated from
HCMV) in blood of AIDS
ence of CMV disease in
y vitritis in CMV retinitis
CMV-disease in AIDStherapy in HIV-infected
ction in HIV co-infected
therapy in HIV infected
ays for CMV viremia in
e cohort of HIV-infected
mination in HIV-infected
of CMV retinitis in AIDS
notransferase (s-alt) in
us encephalitis in eight
dofovir in experienced
ng-term follow-up in 30
European HIV-infected
inal fluid (CSF) of AIDS
us among HIV infected
d CMV retinitis in AIDS
e of CSF JC viral load in
on of HAART in 4 AIDS
or) on HCV viral load in
of CMV retinitis in AIDS
Ileles in Brazilian AIDS
I treatment (HAART) in
dy of oral thalidomide in
F-DDA, lodenosine) in
AIDS-Kaposi's sarcoma
rcoma in AIDS Mexican
ral therapy (HAART) in

oma (PCNSL) in AIDS
ymphoma (AIDS-NHL)
ectious complications in
xorubicin, etoposide) in
58 (HIV+) haemophilia

- GESEDA and GAEI study/Rho 22111
/Streptococcus pneumoniae and 22113
with advanced HIV disease/High 22117; microbiology, risk factors and out 22118
/Non-opportunistic bacterial infec 22119: Results of a prospective study/C 22120
undergoing antiretroviral therapy 22125:The EuroSIDA study/Changes i 22127
with CD4 below 50/ftl/Tuberculo 22128
treated for disseminated tubercul 22130
in Rio de Janeiro, Brazil/Risk fact 22132
/Fever of unknown origin and gra 22134
with tuberculosis: analysis of clini 22137
with prolonged fever/Prediction o 22138
in an out-patient clinic in Belo Hori 22139
in Rio de Janeiro, Brazil/Clinical 22142
with advanced AIDS is decreased 22145
infected and not infected with the 22147, a radiological evaluation/Active 22148
with tuberculosis in Rio de Janeir 22149
in HIV/AIDS clinic G.T. Hospital, 22151
to be accurately diagnosed in urb 453*/22154
and compliance to primary proph 22156
and its consequences on clinical 22157
with HIV infection/Diagnostic use 22160
in Gujarat, India/Pattern of tuberc 22162
/Decreasing incidence of mycoba 22166
in care in the USA: Who is missin 22167
with disseminated MAC disease/ 22169
treated with antiretroviral combin 22180
with AIDS/Withdrawal of Pneum 22186
/Impact of HAART on clinical evol 22192
in Pune, India: Implications for sy 22199
with sexually transmitted disease 22201
with HIV infection/Correlation bet 22214: Role of the sulcus as a reservoir/ 22215: Risk factors and correlates of out 22216
living in an endemic region?/Coc 22220
/Disseminated histoplasmosis in 22224
/Opportunistic fungal infections in 22229
/Long-term serologic study of tox 22231
with AIDS (ANRS 054)/Efficacy a 22232
/Intestinal microsporidiosis as a w 22233
between 1988 and 1995/Inciden 22234
with intestinal microsporidiosis/D 22235
following HAART/Sustained disa 14*/22237
with a history of CMV retinitis rece 16*/22239
is immune mediated/Evidence th 15*/22240
in the era of HAART/Predictive v 22241
with chronic hepatitis C/Long-ter 20*/22242
treated with HAART/Rapidly evol 17*/22243
/Long lasting remission of cytome 22244
with AIDS at risk for CMV end-org 22246
with cytomegalovirus (CMV) retini 22247
(Predivir Cohort): Value of differe 22248
/The role of cytomegalovirus (CM 22251
with HIV and HCV co-infection/In 22252
with AIDS: Clinical and laboratory 22253: Results of the German Cidofovir 22256
/Low CMV disease progression af 22257. Prevalence and prognostic value 22261
without CMV disease/Cytomegal 22262: Evidence of HGV sexual transmi 22264
/Relationship between the detecti 22265
with progressive multifocal leuko 22266
/Long-lasting remission of CMV r 22268
co-infected with HCV-HIV/lmpac 22269
on highly active antirretroviral tre 22271
with cytomegalovirus retinitis (CM 22272
with AIDS-associated Kaposi's s 617*/22275
with AIDS-related Kaposi's sarco 22280
with symptomatic HIV infection/A 22281
/Production of human /-chemoki 22285
/Kaposi's sarcoma in AIDS Mexic 22287
with HIV-related non-Hodgkin's ly 22289

/Predictive value of thallium-201 22291:Pilot study/Idarubicin contained 22294
with HIV-related lymphoma/Infec 22296
(pts) with resistant human immun 22297
/NHL - 17 years follow-up in a Gr 22298

odeficient HIV-infected
n (FUO) in HIV infected
n HIV seropositive adult
pairment in HIV infected
origin in HIV-1 infected
opathic mouth ulcers on
ong Singaporean AIDS
herapy in HIV-infected
3TC) in HIV-1 infected
after virologic relapse in
navir in HIV-1 infected
y in HIV-1 experienced
gistic antiviral effects in
ailure in a cohort of HIV
months in HIV infected
in a cohort of 120 HIV+
survival in HIV infected
ns among HIV-infected
py naive HIV-infected
herapy for HIV-infected
QV in HIV-1 infected
ed HIV-1 infected adult
a and PBMCs in naive
ienced HIV-1 infected
V replication persists in
pretreated HIV-infected
hibitor (PI) experienced
n of HIV-1 replication in
y in antiretroviral-naive
retroviral failure in HIV+
nfection in pretreated
sion infectivity assay in
combination therapy in
ne (ddC) for HIV/AIDS
nterleukin-2 therapy in
in (rlL2) in HIV-infected
S.C. interleukin-2 in HIV
y of care providers and
ds of "palliative care" for
ve care for hospitalized
e complications in AIDS
ome care for HIV/AIDS
ssistance-TDA to AIDS
th AIDS and non-AIDS
ng care for HIV positive
city of nurses to care for
or the care of HIV/AIDS
nd A in genital ulcers in
Ds among HIV infected
tivity among STD clinic
kshop for psychiatric innfection among indigent
ree years of life for HIV
s on a subset of French
h cohort of HIV infected
f the Rorschach of 30
tments/The attitudes of
eeking behavior of STD
Psychiatric disorders in
IV-infected medicaid
mptoms in HIV-infected
e (Marseille)/Psychotic
e (Mexico)/Support for
hem/Empowerment of
s of coping with HIV +ve
caregivers of HIV/AIDS
ocial characteristics of
ifestations in HIV/AIDS
ral load in HIV infected
vity (NA) of HIV infected
mmunity in HIV-infected
sponses in HIV-infected
TL) from HIV-2 positive
DCC) in HIV-1 infected
n sera of HIV-1-infected

es and viral load in AIDS
-cell expansions in HIV
-cells from HIV infected
acterial antigens in HIV
ession of Fas antigen in

Keyword Abstra
with potent anti-retroviral therapy: A prospective study/Fever of un
/Immunogenicity of hepatitis B va
/Neurological sensitive impairme
/Usefulness of bone marrow aspir
with HIV/AIDS/Treatment with ce
in 1996/The initial opportunistic i
refractory to standard triple thera
[DMP 266-004]/A double-blind, p
receiving highly active antiretrovir
receiving nucleoside analogue (N
(ZDV + ddC/ddl) with a low baseli
- Based on in vitro model/Ritona
receiving highly active antiretrovir
followed by a single physician/Co
/Patterns of antiretroviral therapy,Aquitaine (France), 1988-97/Infl
in care in the United States/Rece
/A phase II randomized open labe
resistant to conventional triple the
previously treated with ZDV + dd
/Same antiretroviral combination
with CD4+ T cells counts from 20:Characterization in a phase II, op
receiving HAART despite undete
/Ritonavir-Saquinavir (RTV/SQV)
/Combination therapy with nelfina
treated with nelfinavir in combinat: Results at 72 weeks/Stavudine (
/Salvage therapy for antiretroviral
with less than 200 CD4/mm3/AZ
receiving retroviral therapy/Cell f
with low CD4 cell counts/Antiretr
in San Lazaro Hospital/Efficacy a
with advanced HIV disease on hig
/Experience with proleukin (rlL2) i
/Randomized, controlled phase II
about advanced directives (AD) i
with AIDS/HIV/Changing needs
with terminal AIDS/Palliative car
with tunneled Groshong catheter: A pioneer work in Brazil/Oral he
in Brazil/The role of projects of th
at a mixed ward of the University
in treatment for tuberculosis/Amb
with HIV/AIDS in Nigeria/Improvi
in Singapore/Appropriate hospita
attending STD Clinics in Pune, In
in Yaounde: The need for an impr
/Cocaine use and high-risk sexua
/Health and sexuality workshop fo
/Epidemiology of HIV infection a
using a linked administrative data
included in the Caesar trial/Phar: A modeling approach/Effect of m
from USAC, Abidjan/The Rorsch
to treatments/The attitudes of
in unlicensed private clinics in Chi
with HIV infection/Psychiatric dis
in New Jersey/Serious mental illn
after linkage to primary care/Evol
and HIV/developing a psychiatric
with HIV/AIDS by training their fa
HIV positive, family and social net
/Support group and strategies of c
in rural Zimbabwe/Family caregiv
in a multidisciplinary group of AID
under combined antiretroviral the
receiving HAART/Sequential cha
receiving antiretrovial therapy: D
/Analysis of the nef-specific secre
after highly active antiretroviral tr
frequently cross-react with differe

receiving a recombinant gp160 e
/Anti-chemokine antibodies in ser
/Anti-lymphocyte antibodies and
receiving highly active combinati
/Increased CD69 expression in n
receiving active antiretroviral ther
with HIV1 infection/Effects of tripl

ct--
340*/22323
22326
22327
22328
22329
22331
22332
22338
22340
22342
22343
22344
22350
22351
22354
22355
22360
22370
22371
22375
22376
22382
22383
22386
22388
22390
22391
22400
22401
22402
22403
22407
22408
22409
345*/22412
22413
22420
22430
22431
22433
22451
22453
22455
22463
60*/22467
22468
22488
23353
23360
23414
23556
23595
24121
24128
24133
24156
24164
24167
24221
596*/24222
24231
24241
260*/24257
24268
24318
24319
24372
24374
31102
31108
31115
111*/31142
31149

31152
31161
31162
110*/31165
31171
31175
31178